116 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
28
Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold.
Merck Research Laboratories
2
A molecular dynamics simulation investigation of the relative stability of the cyclic peptide octreotide and its deprotonated and its (CF
University of Oxford
6
Chroman-4-one and chromone based somatostatinß-turn mimetics.
University of Gothenburg
54
SAR exploration at the C-3 position of tetrahydro-ß-carboline sstr3 antagonists.
Merck Research Laboratories
42
Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.
Merck Research Laboratories
4
Treating pain with somatostatin receptor subtype 4 agonists.
Therachem Research Medilab (India)
17
Investigation of Cardiovascular Effects of Tetrahydro-ß-carboline sstr3 antagonists.
Merck Research Laboratories
1
DDD-028: a potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory pain.
University of Missouri
44
Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists.
Merck Research Laboratories
34
Ergoline derivatives as highly potent and selective antagonists at the somatostatin sst 1 receptor.
Novartis Institutes For Biomedical Research
55
SAR of the arylpiperazine moiety of obeline somatostatin sst1 receptor antagonists.
Novartis Institutes For Biomedical Research
25
Identification and SAR of potent and selective non-peptide obeline somatostatin sst1 receptor antagonists.
Novartis Institutes For Biomedical Research
3
Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1,Tyr3]-octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man.
Novartis Pharma
13
The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes.
TBA
15
Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist.
TBA
8
N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation.
TBA
8
Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors.
University of Firenze
33
Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues.
The Clayton Foundation Laboratories For Peptide Biology
26
Highly potent 4-amino-indolo[2,3-c]azepin-3-one-containing somatostatin mimetics with a range of sst receptor selectivities.
Vrije Universiteit Brussel
33
Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.
University of Berne
23
Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity.
Salk Institute
6
Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity.
Salk Institute
5
Novel sst5-selective somatostatin dicarba-analogues: synthesis and conformation-affinity relationships.
University of Firenze
12
Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from rat pituitary cells.
University of California San Diego
18
N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo.
Technische Universit£T M£Nchen
1
NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe1-Tyr3-octreotide.
Technische Universit£T M£Nchen
7
Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSST2 and hSST4. An unexpected effect of the chirality of Trp8 on NMR spectra in methanol.
University of Pennsylvania
19
3-Thio-1,2,4-triazoles, novel somatostatin sst2/sst5 agonists.
Institut Henri Beaufour
18
Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.
Salk Institute
11
Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.
Salk Institute
20
2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery.
Merck Research Laboratories
18
Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist.
Tulane University Health Sciences Center
22
Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity.
Institut Henri Beaufour
39
Potent antagonists of somatostatin: synthesis and biology.
Tulane University School of Medicine
35
Nonpeptide somatostatin agonists with sst4 selectivity: synthesis and structure-activity relationships of thioureas.
Northeast Louisiana University
13
Spiro[1H-indene-1,4'-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists.
Merck Research Laboratories
7
Lanthionine-somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies.
University of California San Diego
15
Novel non-peptide ligands for the somatostatin sst3 receptor.
Institut Henri Beaufour
11
Synthesis of substituted imidazopyrazines as ligands for the human somatostatin receptor subtype 5.
Institut Henri Beaufour
13
N-imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function.
Salk Institute
22
Design, synthesis, and evaluation of novel 3,6-diaryl-4-aminoalkoxyquinolines as selective agonists of somatostatin receptor subtype 2.
Merck Research Laboratories
6
Intramolecular azo-bridge as a cystine disulfide bond surrogate: Somatostatin-14 and brain natriuretic peptide (BNP) analogs.
The Weizmann Institute of Science
29
Biological diversity from a structurally diverse library: systematically scanning conformational space using a pyranose scaffold.
Alchemia
4
Synthesis of DOTA-conjugated multimeric [Tyr3]octreotide peptides via a combination of Cu(I)-catalyzed"click" cycloaddition and thio acid/sulfonyl azide"sulfo-click" amidation and their in vivo evaluation.
Utrecht University
58
Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.
F. Hoffmann-La Roche
1
A synthetic method for peptide-PEG-lipid conjugates: application of octreotide-PEG-DSPE synthesis.
Kuang Tien General Hospital
56
3-Thio-3,4,5-trisubstituted-1,2,4-triazoles: high affinity somatostatin receptor-4 agonist synthesis and structure-activity relationships.
Southern Illinois University
6
From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling.
F. Hoffmann-La Roche
30
Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach.
F. Hoffmann-La Roche
4
New sst4/5-selective somatostatin peptidomimetics based on a constrained tryptophan scaffold.
Vrije Universiteit Brussel
19
Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia.
Merck
65
Side Chain Cyclized Aromatic Amino Acids: Great Tools as Local Constraints in Peptide and Peptidomimetic Design.
Vrije Universiteit Brussel
57
Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.
Bristol Myers Squibb
30
Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist.
Crinetics Pharmaceuticals
6
Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR.
Salk Institute
59
Synthesis and structure-activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: high affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment.
Southern Illinois University Edwardsville
43
Discovery of 4-(3-aminopyrrolidinyl)-3-aryl-5-(benzimidazol-2-yl)-pyridines as potent and selective SST5 agonists for the treatment of congenital hyperinsulinism.
Crinetics Pharmaceuticals
45
Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan.
Salk Institute
26
Design, synthesis, and biological evaluation of novel somatostatin receptor subtype-2 agonists: Optimization for potency and risk mitigation of hERG and phospholipidosis.
Ono Pharmaceutical
12
Novel sst(4)-selective somatostatin (SRIF) agonists. 4. Three-dimensional consensus structure by NMR.
Salk Institute
37
Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Salk Institute
5
Effects of heterocyclic aromatic substituents on binding affinities at two distinct sites of somatostatin receptors. Correlation with the electrostatic potential of the substituents.
University of Pennsylvania
34
Urolinin: The First Linear Peptidic Urotensin-II Receptor Agonist.
Charit£-Universit£Tsmedizin Berlin
8
Human somatostatin receptor specificity of backbone-cyclic analogues containing novel sulfur building units.
Hebrew University
37
Discovery of substituted 3H-pyrido[2,3-d]pyrimidin-4-ones as potent, biased, and orally bioavailable sst2 agonist.
Crinetics Pharmaceuticals
31
Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1).
Salk Institute
18
N-Methyl scan of somatostatin octapeptide agonists produces interesting effects on receptor subtype specificity.
Tulane University Health Sciences Center
34
Nipecotic and iso-nipecotic amides as potent and selective somatostatin subtype-2 receptor agonists.
Merck Research Laboratories
2
Optimization of a somatostatin mimetic via constrained amino acid and backbone incorporation.
University of California
21
Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo.
Tarveda Therapeutics
44
Highly potent cyclic disulfide antagonists of somatostatin.
Tulane University School of Medicine
23
Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization.
Merck Research Laboratories
4
Design, synthesis, and biological activities of potent and selective somatostatin analogues incorporating novel peptoid residues.
University of California San Diego
12
Modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biological diversity. A new route to ether synthesis.
University of Pennsylvania
5
A refined model for the somatostatin pharmacophore: conformational analysis of lanthionine-sandostatin analogs.
University of California San Diego
9
[DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.
Inrastes
4
A tetradecapeptide somatostatin dicarba-analog: Synthesis, structural impact and biological activity.
Institute For Research In Biomedicine (Irb Barcelona)
26
A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.
Novartis Pharma
5
Peptide folding induces high and selective affinity of a linear and small beta-peptide to the human somatostatin receptor 4.
Eth Zurich
10
Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition.
Merck
23
Design and synthesis of a novel series of orally active, selective somatostatin receptor 2 agonists for the treatment of type 2 diabetes.
Takeda Pharmaceutical
43
Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
Industrial Technology Research Institute
24
Imidazol- or 1,2,4-triazol-derivatives and their use
Universite De Lille 2 Droit Et Sante
8
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
Jenrin Discovery
50
3-(4-(benzyloxy)phenyl)hex-4-ynoic acid derivative, method of preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient
Hyundai Pharm
8
Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon
Obshchestvo S Ogranichennoy Otvetstvennostyou “Fusion Pharma”
9
Carbohydrazones as new class of carbonic anhydrase inhibitors: Synthesis, kinetics, and ligand docking studies.
University of Karachi
4
Capture-Tag-Release: A Strategy for Small Molecule Labeling of Native Enzymes.
Fairfield University
5
Inhibitor Fingerprinting of Rhomboid Proteases by Activity-Based Protein Profiling Reveals Inhibitor Selectivity and Rhomboid Autoprocessing.
Technische Universität München
8
Carbonic anhydrase inhibitors: Inhibition of human erythrocyte isozymes I and II with a series of phenolic acids.
Ataturk University
53
Discovering potent inhibitors against the beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ) of Helicobacter pylori: structure-based design, synthesis, bioassay, and crystal structure determination.
Shanghai Institute of Materia Medica
17
Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL.
Yale University
8
Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2.
University of Illinois At Chicago
8
Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease.
Cnrs
7
Crystal structures of constitutive nitric oxide synthases in complex with de novo designed inhibitors.
University of California Irvine
17
Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors.
Universita Di Pisa
19
Design, synthesis, and evaluation of oxygen-containing macrocyclic peptidomimetics as inhibitors of HCV NS3 protease.
Schering-Plough Research Institute
5
Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.
Targegen